Hills Bank & Trust Co Purchases Shares of 934 Novo Nordisk A/S (NYSE:NVO)

Hills Bank & Trust Co acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 934 shares of the company’s stock, valued at approximately $133,000.

Other institutional investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. increased its holdings in shares of Novo Nordisk A/S by 38.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 94,544 shares of the company’s stock worth $9,781,000 after buying an additional 26,067 shares during the last quarter. McKinley Carter Wealth Services Inc. increased its stake in Novo Nordisk A/S by 37.0% in the fourth quarter. McKinley Carter Wealth Services Inc. now owns 60,356 shares of the company’s stock valued at $6,244,000 after acquiring an additional 16,293 shares during the last quarter. Bank of New Hampshire raised its position in Novo Nordisk A/S by 1,356.8% during the first quarter. Bank of New Hampshire now owns 13,257 shares of the company’s stock valued at $1,702,000 after purchasing an additional 12,347 shares in the last quarter. Cim LLC bought a new stake in Novo Nordisk A/S during the fourth quarter worth about $23,547,000. Finally, Burford Brothers Inc. purchased a new position in shares of Novo Nordisk A/S in the 4th quarter worth about $1,045,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Trading Down 1.1 %

NYSE:NVO traded down $1.54 during midday trading on Monday, reaching $135.43. 800,607 shares of the stock traded hands, compared to its average volume of 4,405,647. The stock has a market capitalization of $607.75 billion, a P/E ratio of 46.63, a PEG ratio of 1.33 and a beta of 0.41. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. The company has a fifty day moving average of $136.22 and a 200 day moving average of $131.66. Novo Nordisk A/S has a 12 month low of $86.96 and a 12 month high of $148.15.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Monday, August 26th. Stockholders of record on Friday, August 16th will be paid a dividend of $0.5126 per share. This represents a dividend yield of 0.7%. The ex-dividend date is Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 24.83%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 19th. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. The Goldman Sachs Group began coverage on shares of Novo Nordisk A/S in a report on Thursday, May 30th. They set a “buy” rating and a $156.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday, August 19th. Finally, Argus raised their price objective on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, June 10th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $145.17.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.